leadf
logo-loader
viewActivEX
(
ASX:AIV
)

ActivEX Limited acquiring Queensland copper-gold project from Newcrest Mining

au_qsld__350_528abd52df211.jpg

ActivEX Limited (ASX:AIV) is acquiring the Coalstoun Lakes copper-gold project in Queensland from Newcrest Mining (ASX: NCM) for $200,000.

Coalstoun Lakes, located 100 kilometres northwest of Gympie in south-east Queensland, is a porphyry copper-gold project with significant near surface supergene enrichment – open pit heap leach target.

This is similar to the company’s White Horse supergene target in the same district.

It is confident of bringing both prospects to resource stage quickly and is looking at potential synergies in a combined project development.

Coalstoun Lakes porphyry has peripheral gold dominant breccia and structural targets that have had limited previous drill testing, giving the company immediate drill targets.

The project covers 189.9 square kilometres between Gayndah and Biggenden and has been explored for porphyry copper style mineralisation since discovery in the 1970s.

In recent years, Newcrest has principally focussed on exploring large tonnage gold-copper and gold dominant breccia and epithermal targets which lie adjacent to, and are associated with, the Coalstoun Lakes copper porphyry.

Australian & China focused ASF Group (ASX: AFA) has a 42.75% interest in ActivEX.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: ActivEX

Follow
ASX:AIV

Price: 0.16 AUD

Market Cap: $28.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

CBD Science looks to raise £2M in Series A to advance its plant-based...

CBD Science Group PLC CEO Dr Michael Raymont joined Proactive New York to discuss the London, England-based group's Series A funding round, on the Crowd for Angels platform. Raymont says the privately-held company, which is developing plant-based cannabinoid pharmaceutical therapeutics to...

11 hours, 7 minutes ago

2 min read